Cargando…
A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature
Cutaneous basal cell carcinoma (BCC) is the most common type of human tumor, and its incidence rate is increasing worldwide. Up until a few years ago, therapeutic options have been limited for patients with advanced BCC (including metastatic and locally-advanced BCC). Over the last few years, promis...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696523/ https://www.ncbi.nlm.nih.gov/pubmed/33202689 http://dx.doi.org/10.3390/ijms21228596 |
_version_ | 1783615424186810368 |
---|---|
author | Passarelli, Anna Galdo, Giovanna Aieta, Michele Fabrizio, Tommaso Villonio, Antonio Conca, Raffaele |
author_facet | Passarelli, Anna Galdo, Giovanna Aieta, Michele Fabrizio, Tommaso Villonio, Antonio Conca, Raffaele |
author_sort | Passarelli, Anna |
collection | PubMed |
description | Cutaneous basal cell carcinoma (BCC) is the most common type of human tumor, and its incidence rate is increasing worldwide. Up until a few years ago, therapeutic options have been limited for patients with advanced BCC (including metastatic and locally-advanced BCC). Over the last few years, promising systemic therapies have been investigated for the treatment of advanced BCC. In particular, the Hedgehog signaling inhibition has shown remarkable results for this population. Hedgehog inhibitors, represented by vismodegib and sonidegib, have been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of both locally advanced and metastatic BCC, with, generally, a good safety profile. Notwithstanding the late onset of BCC in the global population, associated with life expectancy increase, only a few clinical trials have evaluated the efficacy and safety profile of Hedgehog inhibitors in this complex and neglected population. Herein, we review the major mechanisms implicated in the pathogenesis of BCC focusing on the Hedgehog signaling pathway and its therapeutic role in the elderly population. Finally, we report two case reports of BCC elderly patients in order to demonstrate both efficacy and safety of the Hedgehog inhibitors. |
format | Online Article Text |
id | pubmed-7696523 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76965232020-11-29 A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature Passarelli, Anna Galdo, Giovanna Aieta, Michele Fabrizio, Tommaso Villonio, Antonio Conca, Raffaele Int J Mol Sci Review Cutaneous basal cell carcinoma (BCC) is the most common type of human tumor, and its incidence rate is increasing worldwide. Up until a few years ago, therapeutic options have been limited for patients with advanced BCC (including metastatic and locally-advanced BCC). Over the last few years, promising systemic therapies have been investigated for the treatment of advanced BCC. In particular, the Hedgehog signaling inhibition has shown remarkable results for this population. Hedgehog inhibitors, represented by vismodegib and sonidegib, have been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of both locally advanced and metastatic BCC, with, generally, a good safety profile. Notwithstanding the late onset of BCC in the global population, associated with life expectancy increase, only a few clinical trials have evaluated the efficacy and safety profile of Hedgehog inhibitors in this complex and neglected population. Herein, we review the major mechanisms implicated in the pathogenesis of BCC focusing on the Hedgehog signaling pathway and its therapeutic role in the elderly population. Finally, we report two case reports of BCC elderly patients in order to demonstrate both efficacy and safety of the Hedgehog inhibitors. MDPI 2020-11-14 /pmc/articles/PMC7696523/ /pubmed/33202689 http://dx.doi.org/10.3390/ijms21228596 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Passarelli, Anna Galdo, Giovanna Aieta, Michele Fabrizio, Tommaso Villonio, Antonio Conca, Raffaele A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature |
title | A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature |
title_full | A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature |
title_fullStr | A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature |
title_full_unstemmed | A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature |
title_short | A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature |
title_sort | vismodegib experience in elderly patients with basal cell carcinoma: case reports and review of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696523/ https://www.ncbi.nlm.nih.gov/pubmed/33202689 http://dx.doi.org/10.3390/ijms21228596 |
work_keys_str_mv | AT passarellianna avismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT galdogiovanna avismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT aietamichele avismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT fabriziotommaso avismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT villonioantonio avismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT concaraffaele avismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT passarellianna vismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT galdogiovanna vismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT aietamichele vismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT fabriziotommaso vismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT villonioantonio vismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature AT concaraffaele vismodegibexperienceinelderlypatientswithbasalcellcarcinomacasereportsandreviewoftheliterature |